Aerosols and anti-infectious agents

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 14, Issue 1, 2001, Pages 55-64

  Diot, P ^a   Dequin, P F ^a   Rivoire, B ^a   Gagnadoux, F ^a   Faurisson, F ^b   Diot, E ^a   Boissinot, E ^a   Le Pape, A ^a   Palmer, L ^c   Lemarie E ^a  

^a CHU BRETONNEAU   (France)

^b INSERM   (France)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Aerosols; Anti infectious drugs; Nebulizers

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COLISTIN; NEOMYCIN; PENTAMIDINE; TOBRAMYCIN;

AEROSOL; ARTICLE; DEVICE; DRUG MONITORING; NEBULIZATION; NEBULIZER; PARTICLE SIZE; ULTRASOUND;

EID: 0035004864     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/08942680152007909     Document Type: Article

References (41)

1. Inhalation of promin in experimental tuberculosis
2. Aerosol polymyxin and pneumonia in seriously ill patients
3. Antibiothérapie en aérosols
4. Inhalation of antibiotics in cystic fibrosis
5. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks
6. Optimisation des conditions d'aérosolisation de la pentamidine: Études granulométriques et isotopiques
7. Aerosols in therapy
8. Errors in characterizing nebulized particle size distributions with cascade impactors
9. Assessment of aerosol delivery systems for recombinant human deoxyribonuclease
10. Nebulization and anti-Pseudomonas aeruginosa activity of colistin
11. Physiopathologic bases
12. Mechanisms of aerosol particle deposition
13. Propositions de bonnes pratiques de l'aérosolthérapie par nébulisation
14. Caractérisation par méthode isotopique des performances du nébeuliseur pneumatique NL9 Atomisor® pour la production d'aérosols de colistine, tobramycine et amiloride
15. Drug delivery systems
16. Aerosol inhalation before reading age
17. Déposition pulmonaire des aérosols de colistine dans la mucoviscidose. Comparison d'un nébuliseur ultrasonique et d'un nébuliseur pneumatique
18. Characterization on the bench of an amikacin aerosol before clinical studies
19. Urinary excretion reflects lung deposition of amikacin aerosols in cystic fibrosis
20. Comparison of inhibitory and bactericidal activity of antipseudomonal antibodies against Pseudomonas aeruginosa isolates from cystic fibrosis patients
21. Ventilatory effects of aerosol gentamicin
22. Bronchial reactivity in cystic fibrosis
23. Bronchial allergy in cystic fibrosis
24. Aerosol characterization and deposition
25. Respirable mass: Vague and indefinable in disease
26. The current laboratory determination of "respirable mass" is not clinically relevant
27. Pharmaceutical formulations. Suspensions and solutions
28. Deposition of amphotericin B aerosols in pulmonary aspergilloma
29. Concepts pour l'évaluation de l'aérosolthérapie dans la mucoviscidose
30. Comparative deposition of inhaled aerosols in experimental animals and humans: A review
31. Clinical observations of aerosol deposition in patients with airway obstruction
32. Deposition of inhaled aerosols
33. Pulmonary deposition of aerosols in children with cystic fibrosis
34. Aerosol therapy in acute and chronic respiratory disease
35. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection
36. Nebulised colimycin for early psaeudomonas colonisation in cystic fibrosis
37. Quantitative deposition of aerosolized gentamicin in cystic fibrosis
38. RhD-Nase I aerosol deposition and related factors in cystic fibrosis
39. Respiratory tract deposition of ultrafine particles in subjects with obstructive or restrictive lung disease
40. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis
41. Aerosolized antibiotics in mechanically ventilated patients: Delivery and response